RM-046, a First-in-class, Mutant-Selective, and Oral KRASQ61H(ON) Inhibitor That Drives Tumor Regression in Preclinical Models and Validates KRASQ61H As a Therapeutic Target
Cancer Research(2023)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined